Mumbai: Fredun Pharmaceuticals Limited has delivered a 40% rise in its annual net profit at ₹33.20 crore from ₹20.03 crore reported last year, thanks to the company’s focus on improving its operational efficiencies and strengthening its balance sheet.
During the year, the company reported a 28.67% rise in revenues from ₹451.70 crore in FY2025 to ₹633.32 crore in FY26 as the company upgraded its manufacturing plants while negotiating better prices for its raw medicine ingredients and optimizing its supply chains. It has also worked to reduce its internal production costs during the year.
Besides this, the company launched its first round-the-clock pet diagnostic center targeted for Tier 1 cities, while also rolling out its premium health and wellness platform DAULCÉL to offer healthcare and wellness goods to premium customers.
“FY2025-26 has been a landmark year in the evolution of Fredun Pharmaceuticals Limited, a year that has not only delivered strong business performance but has also redefined the scale of our ambitions.
FY26 was a year of bold decisions and meaningful milestones. We strengthened our core pharmaceutical business while simultaneously building new growth engines that will shape the future of Fredun for years to come. Our expansion into pet healthcare gained significant momentum through the strategic acquisition of One Pet Stop and the development of Wagr Retail, creating an integrated ecosystem spanning diagnostics, nutrition, wellness, retail, and veterinary care.
The launch of India’s first 24×7 Pet Diagnostic Centre and our dedicated functional foods facility further reinforced our leadership aspirations in this rapidly growing sector. At the same time, we accelerated our entry into the future of healthcare through the launch of DAULCÉL, our premium longevity and wellness platform, and our Hormone Range Products, focused on advanced performance, preventive health, and specialised therapeutics.
What excites us most is not what we have achieved, but what we are becoming. Fredun today is uniquely positioned at the intersection of some of the most attractive healthcare opportunities globally generic pharmaceuticals, animal healthcare, nutraceuticals, cosmeceuticals, longevity solutions, mobility products, and specialty therapeutics.
As healthcare continues to evolve from treatment to prevention, from products to ecosystems, and from medicine to wellness, Fredun is positioning itself ahead of the curve,” Mr. Fredun Nariman Medhora, Managing Director & Chief Financial Officer, Fredun Pharmaceuticals, said in a press release.
Annual Financial Performance Summary
| Fredun Financial Metric | Fiscal Year 2024-25 (FY25) | Fiscal Year 2025-26 (FY26) | Year-on-Year (YoY) Growth % | Core Drivers |
| Total Revenue | ₹451.70Crore | ₹633.32Crore | 28.67% | Driven by strong demand for core pharmaceuticals and the expansion of new wellness brands. |
| Net Profit After Tax | ₹23.71 Crore | ₹33.20 Crore | 40.02% | Surged sharply ahead of revenue growth due to massive savings from improved factory efficiencies. |
| Earnings Per Share (EPS) | ₹49.12 | ₹68.75 | 39.96% | Driven by consistent operational efficiencies and expansion plans. |
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investing in stocks includes financial risks, and past performance is not indicative of future results. Readers should conduct their own research or consult with a qualified financial advisor before making any investment decisions.
